Avant Technologies and JV Partner, Ainnova, Prepare for Key FDA Milestone with Next Week's Pre-Submission Meeting
The pre-submission meeting with Ainnova's executives and its CRO is set for Monday, July 7. The FDA meeting will allow the Company to discuss its planned clinical trial of Ainnova's Vision AI platform in the early detection of diabetic retinopathy. These meetings will give the team the direction it needs for a successful clinical trial and to support the Company's FDA 510(k) submission to obtain clearance from the FDA to market the Vision AI technology in the United States .
Vinicio Vargas , Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, "We're approaching a key milestone. We've been preparing thoroughly with the support of an experienced CRO and expert regulatory advisors, and we're optimistic about the outcome.
"Diabetic retinopathy is the number one cause of preventable blindness worldwide. That's unacceptable—and we believe technology can change that. But this is just the beginning. Retinal screening offers a gateway to detecting many systemic conditions early—like Alzheimer's, cardiovascular disease, and more.
"We're committed to pushing the boundaries of preventive care, improving both life expectancy and quality of life for people around the world. That's the mission behind everything we do."
Ainnova will use this pre-submission meeting to determine a host of items, including the ideal number of clinical sites, the number of total patients needed, and to learn if the FDA will approve the clinical trial protocol for the planned trial. These are all crucial for both Avant and Ainnova in determining the exact costs and a timetable.
AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's interactions with the FDA are paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product.
About Ainnova Tech, Inc.
Ainnova is a Nevada -based healthtech startup with headquarters in San Jose, Costa Rica , and Houston, Texas . Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies, Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is possible in AI and biotechnology, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Trending Stocks By Analyst's for this Week
Analyst Ratings (USA) Aardvark Therapeutics was rated Buy by HC Wainwright, with a target price of $40.00. AbbVie received a Buy rating from Morgan Stanley, with a price target of $250.00. Aemetis had its target raised by UBS Group, reaffirming a Buy rating and lifting the price from $2.20 to $3.00. AeroVironment was initiated with a Buy rating by The Goldman Sachs Group, targeting $301.00. Affirm had its target raised by Barclays and maintained an Overweight rating, with the price increased from $67.00 to $80.00. Agnico Eagle Mines received an Outperform initiation from Raymond James Financial, with a target price of $130.00. Agree Realty was reiterated as Market Perform by JMP Securities. Air Products and Chemicals was reiterated with a Buy rating by Citigroup, increasing the target from $310.00 to $320.00. Alnylam Pharmaceuticals had its target raised by Wells Fargo & Company, maintaining an Equal Weight rating, and the price increased from $287.00 to $333.00. American Healthcare REIT was initiated at Sector Outperform by Scotiabank, with a target of $42.00. Amgen received a Buy rating from TD Cowen, with a price target of $389.00. Amgen was rated Hold by Morgan Stanley, with a target of $330.00. Amplify Energy was initiated with a Buy rating by Alliance Global Partners, with a price target of $6.00. Anglogold Ashanti PLC received a Buy rating from Roth MKM, with a target price of $54.00. Antero Resources was rated Hold by Citi, with a target of $45.00. Aramark was maintained at Equal Weight by Morgan Stanley, with a price target increase from $42.00 to $44.00. Argenx Se also received a Buy rating from Wells Fargo, targeting $741.00. Argenx Se was rated Buy by Citi, with a target price of $803.00. ARM had its target raised by Guggenheim, keeping a Buy rating and lifting the price from $147.00 to $187.00. Aurinia Pharmaceuticals was rated Buy by both Leerink Partners and TD Cowen, with targets of $10.00 and $11.00, respectively. Aytu BioPharma was given a Buy initiation by Ascendiant Capital Markets, with a target price of $12.00. B2Gold was initiated with an Outperform rating by Raymond James Financial, targeting $4.50. Baker Hughes Company was rated Buy by Wells Fargo, aiming for $50.00. Beazer Homes USA was initiated as Neutral by B. Riley, with a target of $23.00. BioCryst Pharmaceuticals had its Outperform rating reiterated by Royal Bank of Canada, with a target of $13.00. BioCryst received a Buy rating from BofA Securities, with a target of $15.00. Boeing was rated Buy by Citi, with a price target of $220.00. Boyd Gaming had its Outperform rating reaffirmed by Raymond James Financial, and its target raised from $81.00 to $85.00. BridgeBio Pharma had its target raised by Wells Fargo & Company, keeping an Overweight rating and raising the price from $67.00 to $76.00. BridgeBio Pharma received a Buy rating from Raymond James, with a price target of $57.00. Brookfield Asset Management was initiated with a Neutral rating by Piper Sandler, targeting $60.00. CAE was initiated with a Buy rating by The Goldman Sachs Group, with a target of $33.00. Candel Therapeutics received a Buy initiation from HC Wainwright, targeting $23.00. Capricor Therapeutics was initiated at Buy by Alliance Global Partners, with a price target of $20.00. CarMax received a Buy rating from Morgan Stanley, with a price target of $80.00. Celcuity had its Buy rating reiterated by Needham & Company LLC, with a target of $29.00. Celcuity received a Buy rating from LifeSci Capital, with a target of $27.00. Cencora was rated Hold by Jefferies Financial Group, with a raised target of $300.00. Century Communities was initiated with a Buy rating by B. Riley, targeting $70.00. Chemed had its Buy rating maintained by Bank of America, though the price target was lowered from $708.00 to $650.00. Cidara Therapeutics had its Market Outperform rating reiterated by JMP Securities, with a target of $59.00. Circle Internet Group was rated Buy by Canaccord Genuity Group, with a target price of $247.00. Circle Internet Group was rated Buy by Citigroup, with a target price of $243.00. Circle Internet Group was rated Buy by Needham & Company LLC, with a target price of $250.00. Circle Internet Group was rated Hold by Deutsche Bank Aktiengesellschaft, with a target price of $155.00. Circle Internet Group was rated Market Perform by Oppenheimer (no price target provided). Circle Internet Group was rated Neutral by The Goldman Sachs Group, with a target price of $83.00. Circle Internet Group was rated Outperform by Sanford C. Bernstein, with a target price of $230.00. Circle Internet Group was rated Overweight by Barclays, with a target price of $215.00. Circle Internet Group was rated Underweight by JPMorgan Chase & Co., with a target price of $80.00. Citius Pharmaceuticals was rated Buy by D. Boral Capital, with a target of $6.00. Clene was rated Buy by D. Boral Capital, with a target price of $23.00. Cloudastructure received a Buy rating from Maxim Group, targeting $6.00. Coeur Mining was rated Buy by Roth MKM, with a target price of $12.00. Cogent Biosciences was rated Neutral by Wedbush, targeting $10.00. Cohen & Steers was initiated with an Underperform rating by Bank of America, targeting $67.00. Comfort Systems USA was rated Buy by DA Davidson, and the price target was raised to $630.00. Concentrix was rated Buy by Canaccord Genuity Group, with a price target of $80.00. Consolidated Edison was upgraded to Outperform by Mizuho, with a target of $107.00. CoreCivic received a Buy rating from Texas Capital Securities, targeting $28.00. CorMedix was downgraded to Hold by D. Boral Capital (no new price target provided). Crocs was rated Buy by Bank of America, with a reduced target of $135.00. CVS Health was rated Buy by Jefferies Financial Group, with a new target of $80.00. Dave was rated Buy by Benchmark, with a raised price target of $320.00. Dayforce was rated Buy by Needham & Company LLC, targeting $95.00. Delek US was rated Outperform by Raymond James Financial, with a price target of $23.00. Dianthus Therapeutics was assigned a Buy rating by LifeSci Capital, with a target of $45.00. DoorDash was rated Outperform by Oppenheimer, targeting $280.00. Driven Brands was initiated as Buy by BTIG Research, targeting $22.00. Duolingo was rated Buy by Evercore ISI, targeting $540.00. Dutch Bros was initiated as Outperform by CICC Research, targeting $80.00. eBay was rated Equal Weight by Wells Fargo & Company, with a new target of $66.00. Edgewise Therapeutics was initiated with a Buy rating by HC Wainwright, with a price target of $42.00. Emerson Electric Company received a Buy rating from KeyBanc, with a price target of $155.00. Etsy was rated Underweight by Wells Fargo & Company, with a raised target of $41.00. Exelixis was rated Buy by HC Wainwright, with a revised target of $53.00. Expand Energy also received a Buy rating from Mizuho Securities, with a target of $142.00. Expand Energy received a Buy rating from Citi, targeting $140.00. Expeditors International of Washington was rated Hold by Truist Financial, with a revised target of $110.00. Expro Group Holdings received a Buy rating from Wells Fargo, with a target price of $12.00. Fabrinet was rated Buy by Fox Advisors, with a target of $335.00. Federal Signal was rated Outperform by Raymond James Financial, with a raised target of $120.00. First Busey was initiated as Market Perform by Hovde Group, with a target of $25.00. First Solar received a Buy rating from Wells Fargo, with a price target of $177.00. Frequency Electronics received a Buy rating from Freedom Capital Markets, targeting $27.00. Fulcrum Therapeutics was rated Sell by BofA Securities, with a price target of $6.00. Gain Therapeutics received a Buy rating from BTIG, with a price target of $10.00. Gain Therapeutics was rated Buy by Roth MKM, with a target price of $7.00. GeneDx was rated Buy by Guggenheim, with an increased target of $115.00. Genius Sports was rated Market Outperform by JMP Securities, with a raised price target of $13.00. Genpact received a Buy rating from Needham & Company LLC, targeting $50.00. Geo Group was also rated Buy by Texas Capital Securities, with a target of $30.00. Green Brick Partners was initiated with a Neutral rating by B. Riley, with a target of $62.00. Grindr received a Market Outperform rating from JMP Securities, with a raised target of $27.00. Guaranty Bancshares was rated Overweight by Stephens, targeting $47.00. GXO Logistics was rated Hold by Truist Financial, with a revised target of $48.00. Hewlett Packard Enterprise received a Buy rating from Bank of America, with a raised target of $23.00. Hippo Holdings was rated Buy by Financial, with a price target of $35.00. Home Depot received a Buy rating from Citi, aiming for $433.00. Home Depot received a Buy rating from Wells Fargo, with a price target of $420.00. Home Depot was rated Outperform by Telsey Advisory Group, targeting $455.00. Howmet Aerospace was rated Outperform by Royal Bank Of Canada. Hyatt Hotels also received a Buy rating from BofA Securities, targeting $150.00. Hyatt Hotels received a Hold rating from Morgan Stanley, targeting $132.00. Hyatt Hotels was rated Buy by Bernstein, targeting $167.00. Iamgold was initiated with a Market Perform rating by Raymond James Financial, targeting $8.00. Indivior was rated Buy by Craig Hallum, with a raised target of $22.00. Inmune Bio was rated Hold by BTIG, with a price target of $21.00. Inuvo received a Buy rating from HC Wainwright, with a target raised to $15.00. Ionis Pharmaceuticals was rated Buy by Barclays, targeting $57.00. It also received a target raise from Wedbush, maintaining the Outperform rating and increasing the price from $16.00 to $18.00. J.B. Hunt Transport Services was rated Hold by Truist Financial, with a new price target of $140.00. Joby Aviation was rated Buy by Canaccord Genuity, with a target of $12.00. KB Home received a Sell rating from CFRA, with a price target of $49.00. Kellanova received a Hold rating from TD Cowen, with a price target of $83.50. Kinross Gold was initiated with a Market Perform rating by Raymond James Financial, targeting $15.00. KKR & Co. Inc. was initiated with an Overweight rating by Piper Sandler, targeting $150.00. Kratos Defense & Security Solutions was upgraded to Buy by The Goldman Sachs Group, targeting $52.00. Krystal Biotech was rated Buy by Clear Street, with a target of $190.00. Largo received a Buy rating from HC Wainwright, targeting $3.70. Lear was rated Buy by Citigroup, with a raised target of $136.00. Leonardo DRS was initiated as Buy by The Goldman Sachs Group, with a target of $49.00. Linde was upgraded to Buy by Citigroup, with a raised target of $535.00. M&T Bank was assigned a Buy rating by RBC Capital, with a target of $200.00. Marathon Petroleum was rated Strong-Buy by Raymond James Financial, with a raised target of $188.00. MasTec was rated Buy by Roth MKM, with a target of $210.00. McDonald's was rated Overweight by KeyCorp, with a revised price target of $325.00. McEwen Mining received a Buy rating from Roth MKM, with a target of $15.00. Medical Properties Trust was rated Sector Perform by Royal Bank Of Canada, with a lowered target of $4.50. Medtronic was upgraded to Peer Perform by Wolfe Research. Microsoft was reiterated with a Positive rating by UBS Group. Mister Car Wash was initiated with a Neutral rating by BTIG Research. Moderna received a Hold rating from Morgan Stanley, targeting $31.00. Neogen was rated Buy by Guggenheim, with a revised target of $10.00. New Gold was initiated with a Market Perform rating by Raymond James Financial, targeting $4.00. Norwegian Cruise Line was rated Neutral by UBS Group, with a reduced price target of $23.00. NOV also received a Hold rating from Citi, targeting $13.00. NOV was rated Sell by Wells Fargo, with a target of $10.00. NU received an Overweight rating from JPMorgan Chase & Co., with a raised target of $16.00. Nuvalent was rated Buy by Goldman Sachs, targeting $105.00. Old Dominion Freight Line was rated Buy by Truist Financial, with an updated target of $180.00. Omeros received a Buy rating from D. Boral Capital, targeting $36.00. Omnicell was rated Buy by Wells Fargo, with a target of $37.00. Oracle also received a Buy rating from TD Cowen, targeting $250.00. Oracle received a Buy rating from Deutsche Bank, with a target of $240.00. Oracle was upgraded to Buy by Stifel Nicolaus, with a target raised to $250.00. OS Therapies was rated Buy by D. Boral Capital, with a target of $20.00. Palomar was rated Outperform by Keefe, Bruyette & Woods, with a revised target of $204.00. Par Pacific received an Outperform rating from Raymond James Financial, with a raised price target of $30.00. Parker Hannifin received a Buy rating from BofA Securities, with a target of $715.00. Pegasystems was rated Buy by Loop Capital, with an increased price target of $60.00. Planet Labs PBC was initiated with a Neutral rating by The Goldman Sachs Group, targeting $4.60. PNC Financial received a Buy rating from RBC Capital, aiming for $195.00. Porch Group received a Buy rating from Financial, targeting $15.00. ProKidney was downgraded to Underperform by Bank of America, with a lowered target of $1.00. Protagonist Therapeutics received a Buy rating from Citi, with a price target of $72.00. Qorvo was also rated Hold by Mizuho Securities, targeting $84.00. Regeneron Pharmaceuticals was downgraded to Hold by Argus. Robinhood Markets received a Buy rating from KeyBanc, targeting $110.00. Robinhood Markets was rated Buy by Barclays, targeting $57.00. Roblox received an Overweight rating from JPMorgan Chase & Co., with a raised target of $120.00. Rocket Lab was initiated with a Neutral rating by The Goldman Sachs Group, targeting $27.00. Rocket Pharmaceuticals received a Hold rating from Morgan Stanley, with a target of $7.00. SailPoint was initiated with an Overweight rating by Cantor Fitzgerald, targeting $29.00. Schlumberger received an Overweight rating from JPMorgan Chase & Co., with a lowered target of $44.00. Schlumberger was rated Buy by Wells Fargo, targeting $43.00. SEI Investments was rated Outperform by Oppenheimer, with a raised target of $96.00. SharkNinja, Inc. was rated Buy by Jefferies, with a target of $175.00. Skyworks Solutions received a Hold rating from Mizuho Securities, with a target of $75.00. Smurfit Westrock received an Overweight rating from Barclays, with a slightly lowered target of $63.00. Southern Copper received a Hold rating from UBS, with a price target of $105.00. Starbucks was initiated with an Outperform rating by CICC Research, targeting $100.00. Stevanato Group was reiterated as Outperform by William Blair. Strategy was rated Buy by TD Cowen, targeting $590.00. Summit Therapeutics received a Buy rating from UBS, with a target of $30.00. Synopsys received a Hold rating from Wells Fargo, with a price target of $520.00. TD SYNNEX was rated Buy by Loop Capital, with an increased target of $160.00. Tempus AI was rated Buy by Guggenheim, with a raised target of $75.00. Tesla received a Buy rating from Deutsche Bank, with a price target of $345.00. Tesla was rated Buy by Morgan Stanley, with a price target of $410.00. Tesla was reiterated as Buy by Canaccord Genuity Group, with a target of $303.00. Transdigm Group was rated Buy by BofA Securities, with a price target of $1,615.00. Tronox was downgraded to Underperform by BMO Capital Markets, with a reduced target of $3.00. Tyra Bioscience was rated Buy by Oppenheimer, targeting $30.00. Unifirst received a target price of $197.00 set by Robert W. Baird. Unifirst was rated Underweight by Barclays, with a price target of $152.00. Unifirst was reiterated as Neutral by UBS Group. United Therapeutics was rated Buy by UBS Group, with a lowered target of $385.00. US Bancorp was rated Buy by RBC Capital, with a price target of $50.00. US Gold was assigned a Buy rating by Roth MKM, aiming for $18.00. Valero Energy was rated Strong-Buy by Raymond James Financial, with a raised target of $155.00. Vipshop received an Overweight rating from JPMorgan Chase & Co., with a decreased target of $18.00. Vipshop was given a Hold rating by Citi, with a target of $17.00. Virgin Galactic was initiated with a Neutral rating by The Goldman Sachs Group, targeting $3.00. Vor Biopharma was upgraded to Buy by HC Wainwright, targeting $3.00. Wabash National received a Hold rating from D.A. Davidson, with a target of $9.50. Walt Disney was upgraded to Buy by Jefferies Financial Group, with a target of $144.00. Waystar was initiated with an Outperform rating by Mizuho, targeting $48.00. Whirlpool was upgraded to Buy by Longbow Research, targeting $145.00. Wingstop was rated Buy by BTIG, with a target of $430.00. Winnebago Industries was rated Buy by Benchmark, with a reduced price target of $42.00. XPO was rated Buy by Truist Financial, with a raised target of $135.00. Zai Lab received an Outperform rating from Leerink Partners, with a revised target of $75.00. Zai Lab was assigned a Buy rating by Citi, with a target of $66.00. Zai Lab was rated Buy by Leerink Partners, with a price target of $75.00. Zynex was reiterated as Buy by HC Wainwright, targeting $8.00.
Globe and Mail
2 hours ago
- Globe and Mail
Strategy Updates on Share Sales and Bitcoin Acquisition
Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. The latest update is out from Strategy ( (MSTR)). On June 30, 2025, Strategy announced updates to its at-the-market offering programs and bitcoin holdings. The company sold shares worth $578.1 million from June 23 to June 29, 2025, and acquired 4,980 bitcoins using proceeds from these sales. Additionally, Strategy declared and funded quarterly dividends for its STRK and STRF shares, highlighting its strategic financial maneuvers to bolster its market position. The most recent analyst rating on (MSTR) stock is a Buy with a $195.00 price target. To see the full list of analyst forecasts on Strategy stock, see the MSTR Stock Forecast page. Spark's Take on MSTR Stock According to Spark, TipRanks' AI Analyst, MSTR is a Neutral. The overall stock score of 48 reflects significant financial challenges with high leverage and negative cash flow. While the company's strategic focus on Bitcoin and innovative capital market strategies are promising, the ongoing legal issues and negative valuation metrics weigh heavily on the stock's outlook. To see Spark's full report on MSTR stock, click here. More about Strategy Strategy, operating under the name MicroStrategy Incorporated, is a company involved in the financial industry, focusing on securities offerings and bitcoin holdings. The company provides information on market prices, bitcoin purchases, and key performance indicators through its online dashboard, aiming to maintain transparency and comply with disclosure obligations. Average Trading Volume: 14,439,984 Technical Sentiment Signal: Strong Buy Current Market Cap: $105B Learn more about MSTR stock on TipRanks' Stock Analysis page.
CTV News
2 hours ago
- CTV News
Former Toronto Maple Leaf Mitch Marner looks forward to fitting into family culture of Vegas Golden Knights
Newly acquired Golden Knights forward Mitch Marner, left, poses for a photo with his jersey alongside Golden Knights general manager Kelly McCrimmon at City National Arena on Tuesday, July 1, 2025, in Las Vegas. (Chase Stevens/Las Vegas Review-Journal via AP) LAS VEGAS (AP) — Family. Winning. Culture. All three have become synonymous with the Vegas Golden Knights through their first eight years in the NHL. They matched the attributes on Mitch Marner's list and why he agreed to a sign-and-trade from Toronto to Vegas, ultimately leaving the organization that drafted him fourth overall in 2015, two years before the Knights entered the league. 'Obviously, the winning regimen they've put up through the last five years, really since they've been in the league,' Marner said during his introductory news conference Tuesday. 'The living arrangements from talking to (Max) Pacioretty and Reavo (Ryan Reaves) just through the last couple weeks, it seemed like everything was a pretty good fit for my wife and I and our new son. 'And you know, the great players they have here. It's where we wanted to be.' Of course, a $96 million contract for a maximum of eight years didn't hurt, either. Both Marner and Vegas general manager Kelly McCrimmon said it was important to get the deal done before July 1, when Marner would have been eligible to go anywhere else and would have been the most sought-after player beginning at noon EDT. 'This was a spot that was very high on my list,' said Marner, with his wife Stephanie and 3-month-old son Miles in the front row, along with his parents, Paul and Bonnie. 'We wanted to come here and went back to my agent and said I'm open to doing this if we can find a way to do it. A couple hours later Kelly called me and said we got a deal going on. 'We thought about going to free agency, but this is the place we want to be. We didn't want to lose that opportunity. And we want to join this hockey team.' Marner joins Vegas' talented and successful core of Mark Stone, Jack Eichel, William Karlsson, Shea Theodore and Adin Hill, which has made the playoffs three years in a row under coach Bruce Cassidy, including winning the Stanley Cup in 2023. 'You want to be in a place where you want to win,' Marner said. 'That's the whole goal of why we do this, you want to hoist that Stanley Cup. This team has shown that they can do it. I'm lucky enough now to hopefully bring another piece in to help bring it back here.' The deal for Marner opened up after Vegas announced veteran defenseman Alex Pietrangelo was stepping away from hockey because his hip injury would require bilateral femur reconstruction that McCrimmon said had 'no guarantee of success.' Pietrangelo going on long-term injured reserve in part paves the way for the Golden Knights to fit Marner in under the salary cap. McCrimmon said Tuesday he doesn't believe Pietrangelo will ever play hockey again. Marner, however, has plenty to offer the Knights, as the two-time All-Star winger leaves the Maple Leafs as their fifth-highest scorer in franchise history at 741 points in the regular season on 221 goals (14th) and 520 assists (fourth). The 28-year-old's 521 assists since his rookie season (2016-17) ranks fifth in the NHL, while he ranks eighth with 741 points. 'We're getting one of the best forwards in the National Hockey League,' said McCrimmon, who also said that conversations about acquiring Marner went back to the trade deadline. 'Elite playmaker, tremendous passer. ... Our fans will love this player. He really adds to our team. He adds to our offense. It gives us another F1 star at the forward position, which we really feel is important. I think that it improves our team tremendously. 'When it appeared that Mitch would be going to free agency, he was our target. He was the player that we wanted.' AP Hockey Writers Stephen Whyno and John Wawrow contributed to this report. W.g. Ramirez, The Associated Press
